Systemic Inflammatory Markers in B-cell Neoplasm

Официальное название

Systemic Inflammatory Markers As a Prognostic Index for B-cell Neoplasm , Single Center Experience .

Обзор

This study was to evaluate the role of systemic inflammatory markers in predicting outcome for patients with B cell neoplasm

Подробное описание

In malignant tumors, Inflammation plays a crucial role in the development, invasion, and metastasis of malignant tumors. Cancer is often described as a wound that does not heal, highlighting the significance of inflammation in cancer progression. Many tumors are heavily infiltrated by immune cells, including macrophages, neutrophils, and lymphocytes. Therefore, markers related to inflammation and the host immune response are pertinent as biological indicators of B-cell neoplasm progression. Inflammation contributes significantly to the initiation and advancement of B-cell neoplasms by providing nutrients to tumor cells, promoting cell growth, and disrupting immune homeostasis. Various composite indices based on circulating inflammatory cells have been developed as straightforward measures to assess systemic inflammation. Elevated serum inflammatory markers reflect the body's response to malignant tumors. Pro-inflammatory cytokines and inflammatory cells within the tumor microenvironment have been shown to promote tumor growth, induce DNA damage, facilitate angiogenesis, suppress the immune system, and correlate with poor patient survival outcomes. Targeting cytokine receptors or other components in inflammatory pathways involved in metastasis may offer therapeutic potential for malignant tumors. Given the pivotal role of inflammation in cancer biology, identifying novel immune markers is essential for predicting the prognosis of patients with Diffuse Large B-Cell Lymphoma (DLBCL). patients

Первичные конечные точки

• Determination of Optimal Cut-off Values for Systemic Inflammatory Indices in B-cell Neoplasms Using Laboratory Blood Tests [Срок оценки: Baseline]

Вторичные конечные точки (1)

• Prognostic Value of Baseline Systemic Inflammatory Markers on Overall Survival in B-cell Neoplasm Patients [Срок оценки: From baseline up to 8 months]

Критерии участия

Критерии включения

• Individuals newly diagnosed with B-cell neoplasms, including:
• Burkitt's lymphoma (BL)
• Chronic lymphocytic leukemia (CLL)
• Diffuse large B-cell lymphoma (DLBCL)
• Follicular lymphoma (FL)
• Hairy cell leukemia (HCL)
• Splenic B-cell lymphoma/leukemia with prominent nucleoli (SBLPN)
• High-grade B-cell lymphoma (HGBL)
• Lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia
• Mantle cell lymphoma (MCL)
• Splenic marginal zone lymphoma (MZL)
• Monoclonal B-cell lymphocytosis (MBL)
• Multiple myeloma (plasma cell myeloma)
• Monoclonal gammopathy of undetermined significance (MGUS)
• Age 18 years or older.

Критерии исключения

• Individuals previously diagnosed with B-cell neoplasms.
• Individuals younger than 18 years.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Египет · 1 центр

• Assiut University — Asyut

Публикации

• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013 Nov;13(11):759-71. doi: 10.1038/nrc3611. PMID 24154716
• Liu FT, Jia L, Wang P, Farren T, Li H, Hao X, Agrawal SG. CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2016 May 15;22(10):2462-9. doi: 10.1158/1078-0432.CCR-15-1139. Epub 2015 Dec 28. PMID 26712690
• Drutskaya MS, Nosenko MA, Atretkhany KS, Efimov GA, Nedospasov SA. [Interleukin-6 From molecular mechanisms of signal transduction to physiological properties and therapeutic targeting]. Mol Biol (Mosk). 2015 Nov-Dec;49(6):937-43. doi: 10.7868/S0026898415060063. Russian. PMID 26710772
• Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, Hauser C, Mende MM, Legler K, Rocken C, Becker T, Waetzig GH, Rose-John S, Kalthoff H. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. Int J Cancer. 2015 Sep 1;137(5):1035-46. doi: 10.1002/ijc.29445. Epub 2015 Jan 29. PMID 25604508
• Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.115 PMID 23659971
• Beguelin W, Sawh S, Chambwe N, Chan FC, Jiang Y, Choo JW, Scott DW, Chalmers A, Geng H, Tsikitas L, Tam W, Bhagat G, Gascoyne RD, Shaknovich R. IL10 receptor is a novel therapeutic target in DLBCLs. Leukemia. 2015 Aug;29(8):1684-94. doi: 10.1038/leu.2015.57. Epub 2015 Mar 3. PMID 25733167
• Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013 Dec 15;19(24):6812-9. doi: 10.1158/1078-0432.CCR-13-1879. Epub 2013 Oct 18. PMID 24141626
• Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 1;120(18):3783-92. doi: 10.1182/blood-2012-04-424630. Epub 2012 Sep 11. PMID 22968454

Идентификаторы

NCT: NCT06847529 · markers In B-cell tumors

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗